Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tizanidine hydrochloride for migraine prevention in adults
ChiCTR2300072407Phase 4Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tizanidine in migraine (3 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Change from baseline in mean number of migraine days per 4 weeks over the 12-week treatment period. Started Jun 2023; status: recruiting.
02
Drugs
tizanidine
03
Conditions
migraine
Beyond the preview
Go deeper on ChiCTR2300072407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072407.